Lexicon Pharmaceuticals (LXRX) Cash from Investing Activities (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Cash from Investing Activities data on file, last reported at -$70.3 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$70.3 million, down 273.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.2 million (down 98.39% YoY), and the FY2025 annual result was $113.0 million, up 834.95% from the prior year.
• Cash from Investing Activities slipped to -$70.3 million in Q1 2026 per LXRX's latest filing, from $4.8 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $53.7 million in Q4 2024 and troughed at -$110.2 million in Q1 2024.
• A 5-year average of -$5.5 million and a median of $4.8 million in 2025 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities slumped 19199.0% in 2022, then surged 374.34% in 2023.
• A 5-year view of Cash from Investing Activities shows it stood at $24.2 million in 2022, then soared by 114.69% to $51.9 million in 2023, then advanced by 3.47% to $53.7 million in 2024, then slumped by 91.01% to $4.8 million in 2025, then plunged by 1554.72% to -$70.3 million in 2026.
• Business Quant data shows LXRX's Cash from Investing Activities at -$70.3 million in Q1 2026, $4.8 million in Q4 2025, and $52.1 million in Q3 2025.